# US 2019/0169572 A1 · End-to-end cell therapy automation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169572 A1
- Document ID: US20190169572A1
- Status: Published application
- Kind: A1
- Application number: 16/119,618
- Filed: 2018-08-31
- Published: 2019-06-06
- Earliest claimed: 2017-09-01
- Assignees: Lonza Walkersville, Inc.; Lonza Cologne GmbH; Octane Biotech Inc.
- Applicants: Lonza Walkersville, Inc.; Lonza Cologne GmbH; Octane Biotech Inc.
- Inventors: Yaling SHI; Erika McAfee; Samatha Bandapalle; Ann Siehoff; Timo Gleissner; Joseph O'Connor; Eytan Abraham; Kelly Purpura; Nuala Trainor; Timothy Smith
- Web page: https://patentgrep.com/patent/US20190169572A1

## CPC

- C12N 5/0636: {T lymphocytes}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4205: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70521: {CD28, CD152}
- C12M 23/42: {Integrated assemblies, e.g. cassettes or cartridges}
- C12M 29/20: {Degassing; Venting; Bubble traps (means for collection or storage of gas C12M23/36; gas collection apparatus for laboratory use B01L5/02)}
- C12M 41/00: {Means for regulation, monitoring, measurement or control, e.g. flow regulation (controlling or regulating chemical, physical or physicochemical processes B01J19/0006; heating or cooling apparatus for laboratory use B01L7/00; electro optical investigation of individual particles, flow cytometers G01N15/14; automatic analysis G01N35/00; controlling or regulating in general G06N)}
- C12M 41/48: {Automatic or computerized control (automatic analysis G01N35/00)}
- C12N 5/0018: {Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)}
- C12N 5/163: {one of the fusion partners being a B or a T lymphocyte}
- C12N 15/86: Viral vectors
- A61K 2239/59: Reproductive system, e.g. uterus, ovaries, cervix or testes
- C12N 2510/00: Genetically modified cells
- C12N 2740/10041: Use of virus, viral particle or viral elements as a vector
- C12N 2740/15041: Use of virus, viral particle or viral elements as a vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}

## Abstract

The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

## Claims

### Claim 1

A method for automated production of a genetically modified immune cell culture, the method comprising:
(a) activating an immune cell culture with an activation reagent to produce an activated immune cell culture;
(b) transducing the activated immune cell culture with a vector, to produce a transduced immune cell culture;
(c) expanding the transduced immune cell culture;
(d) concentrating the expanded immune cell culture of (c); and
(e) harvesting the concentrated immune cell culture of (d) to produce a genetically modified immune cell culture,
further comprising washing either or both the expanded immune cell culture and the concentrated immune cell culture,
wherein (a) through (e) are performed by a fully enclosed cell engineering system and (a) through (e) are optimized via a process to produce the genetically modified immune cell culture.

### Claim 2 (depends on 1)

The method of claim 1, wherein the process is a self-adjusting process and includes:
(a) monitoring with one or more of a temperature sensor, a pH sensor, a glucose sensor, an oxygen sensor, a carbon dioxide sensor, and an optical density sensor; and
(b) adjusting one or more of a temperature, a pH level, a glucose level, an oxygen level, a carbon dioxide level, and an optical density of the transduced T cell culture, based on the monitoring.

### Claim 3 (depends on 1)

The method of claim 1, wherein the method produces at least about 100 million viable genetically modified immune cells.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein the immune cell culture is a T cell culture.

### Claim 6 (depends on 5)

The method of claim 5, wherein T cell culture is a chimeric antigen receptor T (CAR T) cell culture.

### Claim at position 7

7-16. (canceled)

### Claim 17 (depends on 1)

The method of claim 1, wherein the transducing comprises viral infection, electroporation, membrane disruption, or combinations thereof.

### Claim at position 9

18-20. (canceled)

### Claim 21 (depends on 1)

The method of claim 1, wherein the oxygen level of the transduced immune cell culture is optimized for the immune cell culture.

### Claim 22 (depends on 1)

The method of claim 1, wherein the cell engineering system recirculates cell culture media through an oxygenation component during one or more of steps (a) to (e), and wherein the cell engineering system recirculates nutrients, waste, released cytokines, and/or dissolved gasses during steps (a) to (e).

### Claim at position 12

23-27. (canceled)

### Claim 28 (depends on 1)

The method of claim 1, wherein the cell engineering system comprises a plurality of chambers, and wherein each of steps (a) to (e) is performed in a different chamber of the plurality of chambers of the cell engineering system.

### Claim at position 14

29-30. (canceled)

### Claim 31

A method for promoting a preferred phenotype of a genetically modified immune cell culture, the method comprising:
(a) activating an immune cell culture with an activation reagent to produce an activated immune cell culture, wherein the activation reagent and activating conditions promote the phenotype of the genetically modified immune cell culture;
(b) transducing the activated immune cell culture with a vector, to produce a transduced immune cell culture;
(c) expanding the transduced immune cell culture;
(d) concentrating the expanded immune cell culture of (c); and
(e) harvesting the concentrated immune cell culture of (d) to produce a genetically modified immune cell culture,
wherein (a) through (e) are performed by a fully enclosed, automated cell engineering system.

### Claim at position 16

32-62. (canceled)

### Claim 63 (depends on 96)

The method of claim 96,
wherein each of (a) through (e) are performed with immune cell cultures having an optimized cell density (cells/mL) and an optimized cell confluency (cells/cm2).

### Claim at position 18

64-95. (canceled)

### Claim 96

A method for automated production of a genetically modified immune cell culture, the method comprising:
(a) activating an immune cell culture with an activation reagent to produce an activated immune cell culture;
(b) transducing the activated immune cell culture with a vector, to produce a transduced immune cell culture;
(c) expanding the transduced immune cell culture, wherein the transduced cell culture is not shaken during the expanding;
(d) concentrating the expanded immune cell culture of (c); and
(e) harvesting the concentrated immune cell culture of (d) to produce a genetically modified immune cell culture,
wherein (a) through (e) are performed by a fully enclosed, automated cell engineering system.

### Claim 97 (depends on 96)

The method of claim 96, wherein the activation reagent comprises an antibody or a dendritic cell.

### Claim 98 (depends on 97)

The method of claim 97, wherein the antibody is immobilized on a surface.

### Claim 99 (depends on 98)

The method of claim 98, wherein the surface is a surface of a bead.

### Claim 100 (depends on 97)

The method of claim 97, wherein the antibody is a soluble antibody.

### Claim 101 (depends on 97)

The method of claim 97, wherein the antibody comprises at least one of an anti-CD3 antibody, an anti-CD28 antibody and an anti-CD2 antibody.

### Claim 102 (depends on 96)

The method of claim 96, wherein the method produces at least about 100 million viable genetically modified immune cells.

### Claim 103

(canceled)

### Claim 104 (depends on 96)

The method of claim 96, wherein the immune cell culture is a T cell culture.

### Claim 105 (depends on 104)

The method of claim 104, wherein T cell culture is a chimeric antigen receptor T (CAR T) cell culture.

### Claim 106 (depends on 105)

The method of claim 105, wherein the vector encodes a chimeric antigen receptor.

### Claim 107 (depends on 96)

The method of claim 96, wherein the immune cell culture comprises peripheral blood mononuclear cells and/or purified T cells.

### Claim 108 (depends on 96)

The method of claim 96, wherein the cell culture comprises at least one accessory cell.

### Claim 109 (depends on 108)

The method of claim 108 wherein the accessory cell comprises a monocyte or a monocyte-derived cell.

### Claim 110 (depends on 109)

The method of claim 109, wherein the accessory cell comprises antigens for a T cell receptor, including CD28, CD40, CD2, CD40L and/or ICOS.

### Claim 111 (depends on 96)

The method of claim 96, wherein the transducing comprises viral infection, electroporation, membrane disruption, or combinations thereof.

### Claim 112 (depends on 96)

The method of claim 96, wherein the vector is a lentiviral vector or a retrovirus.

### Claim 113 (depends on 96)

The method of claim 96, wherein the transducing comprises mixing the vector in cell culture media and delivering the vector in the media uniformly to the activated immune cell culture.

### Claim 114 (depends on 96)

The method of claim 96, wherein the expanding comprises at least one or more of feeding, washing, monitoring, and selecting of the transduced immune cell culture, without shaking the immune cell culture.

### Claim 115 (depends on 96)

The method of claim 96, wherein an oxygen level of the transduced immune cell culture is optimized for the immune cell culture.

### Claim 116 (depends on 96)

The method of claim 96, wherein the cell engineering system recirculates cell culture media through an oxygenation component during one or more of steps (a) to (e).

### Claim 117 (depends on 96)

The method of claim 96, wherein the cell engineering system recirculates nutrients, waste, released cytokines, and/or dissolved gasses.

### Claim 118 (depends on 96)

The method of claim 96, wherein a carbon dioxide level provided by the cell engineering system decreases during step (c).

### Claim 119 (depends on 96)

The method of claim 96, wherein the cell engineering system is configured to perform several rounds of feeding, washing, monitoring, and selecting of the transduced immune cell culture.

### Claim 120 (depends on 96)

The method of claim 96, wherein the concentrating comprises centrifugation, supernatant removal following sedimentation, or filtration.

### Claim 121 (depends on 96)

The method of claim 96, wherein the cell engineering system comprises a plurality of chambers, and wherein each of steps (a) to (e) is performed in a different chamber of the plurality of chambers of the cell engineering system.

### Claim 122 (depends on 96)

The method of claim 96, further comprising removing the activation reagent from the activated immune cell culture after step (a).

### Claim 123 (depends on 96)

The method of claim 96, further comprising removing the vector following the transducing in (b).

### Claim 124 (depends on 96)

The method of claim 96, wherein the cell engineering system contains the cell culture of (a), the activation reagent, the vector, and cell culture medium prior to starting the method.

### Claim 125

A method for automated production of a genetically modified immune cell culture, the method performed by a cell engineering system, comprising:
(a) activating an immune cell culture with an activation reagent to produce an activated immune cell culture in a first chamber of the cell engineering system;
(b) transducing the activated immune cell culture, the transducing comprising:
i. transferring the activated immune cell culture from the first chamber to an electroporation unit;
ii. electroporating the activated immune cell culture with a vector, to produce a transduced immune cell culture;
iii. transferring the transduced immune cell culture to a second chamber of the cell engineering system;
(c) expanding the transduced immune cell culture;
(d) concentrating the expanded immune cell culture of (c); and
(e) harvesting the concentrated immune cell culture of (d) to produce a genetically modified cell culture.

### Claim 126 (depends on 125)

The method of claim 125, wherein the transducing comprises:
i. transferring via a first sterile, closed connection, the activated immune cell culture from the first chamber to the electroporation unit;
ii. electroporating the activated immune cell culture with the vector, to produce the transduced immune cell culture;
iii. transferring via a second sterile, closed connection, the transduced immune cell culture to the second chamber of the cell engineering system.

### Claim at position 50

127-156. (canceled)

### Claim 157

A cassette for use in an automated cell engineering system, comprising:
(a) a low temperature chamber, for storage of a cell culture media;
(b) a high temperature chamber for carrying out activation, transduction and expansion of an immune cell culture,
wherein the high temperature chamber is separated from the low temperature chamber, by a thermal barrier,
the high temperature chamber including a cell culture chamber; and
(c) one or more fluidics pathways connected to the cell culture chamber, wherein the fluidics pathways provide recirculation, removal of waste and homogenous gas exchange and distribution of nutrients to the cell culture chamber without disturbing cells within the cell culture chamber.

### Claim at position 52

158-180. (canceled)
